Image Place holder

Richard Kim, MD


Specialty: Medical Oncology
Program: Gastrointestinal Oncology

Call 1-888-MOFFITT
(1-888-663-3488)

or call 1-888-MOFFITT
(1-888-663-3488)

Overview

Dr. Richard Kim is an medical oncologist in the Gastrointestinal Oncology Department at Moffitt Cancer Center.  He is an assistant professor of oncology at the University of South Florida College of Medicine.Dr. Kim’s clinical and research interests focus on gastrointestinal tumors, in particular hepatobiliary and colon cancer.  He is a principal investigator in multiple investigator-initiated and pharmaceutical phase I and II trials using novel targeted agents. Dr. Kim received his medical degree from the University of Miami School of Medicine and completed a residency in internal medicine at the University of Illinois at Chicago.  He pursued a post-doctoral fellowship in hematology and medical oncology at Yale University Comprehensive Cancer Center in New Haven, CT. Before coming to Moffitt in 2010, Dr. Kim was an associate physician in gastrointestinal malignancies at the Cleveland Clinic Taussig Cancer Center and a clinical assistant professor at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University in Cleveland, OH. Dr. Kim was named 2008 Teacher of the Year at the Cleveland Clinic and selected for the 2008 Southwest Oncology Group Young Investigator Program and SWOG’s Intergroup Colon Task Force for junior faculty. Dr. Kim has been an ad hoc editorial reviewer for many professional publications, including Digestive and Liver Disease and Lancet Oncology. Dr. Kim is fluent in English and Korean.  

Education & Training

Board Certification:

  • Medical Oncology

Residency:

  • University of Illinois - Internal Medicine

Medical School:

  • University of Miami School of Medicine - MD
Participating Trials

CLINICAL TRIAL 17932
A Phase 1a/1b Trial of Trametinib in Combination with Sorafenib in Patients with Advanced Hepatocellular Cancer
Condition: Gastrointestinal Tumor
Intervention: BAY 43-9006 (Sorafenib); GSK1120212 (Trametinib); Sorafenib; Trametinib
Open

CLINICAL TRIAL 18435
Phase II study of Copanlisib (BAY 80-6946) in Combination with Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma
Condition: Gastrointestinal Tumor
Intervention: BAY 80-6946 (Copanlisib); Copanlisib; Gemzar (gemcitabine); cisplatin; gemcitabine
Open

CLINICAL TRIAL 18684
A Phase II Investigator Sponsored Study of Nivolumab in Patients with Advanced Refractory Biliary Tract Cancers
Condition: Gastrointestinal Tumor
Intervention: BMS-936558 (Nivolumab); Nivolumab
Open

CLINICAL TRIAL 17651
Multi Institutional Phase II Trial of Single Agent Regorafenib in Refractory Advanced Biliary Cancers
Condition: Gastrointestinal Tumor
Intervention: BAY 73-4506 (Regorafenib); Regorafenib
Open

CLINICAL TRIAL 18322
A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BLU-554 in Patients with Hepatocellular Carcinoma
Condition: Gastrointestinal Tumor
Intervention: BLU-554
Open

CLINICAL TRIAL 18646
Phase I Study of Pre-operative Capecitabine and Lenvatinib with External Radiation Therapy in Locally Advanced Rectal Adenocarcinoma
Condition: Gastrointestinal Tumor
Intervention: E7080 (Lenvatinib); Lenvatinib (Lenvima); Xeloda (capecitabine); capecitabine
Open

CLINICAL TRIAL 18855
Multicenter, Open-label, Phase 1, Dose-escalation,Cohort-expansion, First-in-Human Study of KHK2455 Administered as Monotherapy and in Combination with Mogamulizumab (KW-0761) in Adult Subjects with Locally Advanced or Metastatic Solid Tumors
Condition: Multiple
Intervention: KHK2455; KW-0761 (Mogamulizumab); Mogamulizumab
Open

CLINICAL TRIAL 18739
A Phase 1 Dose Escalation And Cohort Expansion Study Of ERY974, AN ANTI-GLYPICAN 3 (GPC3)/CD3 Bispecific Antibody, In Patients With Advanced Solid Tumors
Condition: Gastrointestinal Tumor
Intervention: ERY974
Open

CLINICAL TRIAL 17986
Phase 1 Study of Mogamulizumab (KW-0761) in Combination with MEDI4736 (Durvalumab) and Mogamulizumab in Combination with Tremelimumab in Subjects with Advanced Solid Tumors
Condition: Multiple
Intervention: CP-675,206 (tremelimumab); KW-0761 (Mogamulizumab); MEDI4736 (Durvalumab); Mogamulizumab; Not Applicable; tremelimumab
Open

CLINICAL TRIAL 18837
An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors
Condition: Multiple
Intervention: Dexamethasone; Rovalpituzumab Tesirine
Open

CLINICAL TRIAL 18906
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors
Condition: Multiple
Intervention: BMS-936558 (Nivolumab); Nivolumab; TSR-022; TSR-042
Open

CLINICAL TRIAL 17690
A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients with Hepatic Dysfunction
Condition: Multiple
Intervention: GSK1120212 (Trametinib); Trametinib
Open

CLINICAL TRIAL 18675
Phase II Trial of FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas
Condition: Gastrointestinal Tumor
Intervention: 5-fluorouracil; CPT-11 (irinotecan); Camptosar (irinotecan); Oxaliplatin; eloxatin (Oxaliplatin); irinotecan; leucovorin
Open

CLINICAL TRIAL 18825
A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1522 in Patients with Advanced Breast Cancer and Other Advanced Tumors Expressing HER2
Condition: Multiple
Intervention: XMT-1522
Open

CLINICAL TRIAL 18832
A Platform Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of INCB Combinations in Advanced Solid Tumors
Condition: Multiple
Intervention: Epacadostat; INCB024360 (Epacadostat); INCB039110; INCB050465
Open

CLINICAL TRIAL 18561
A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors (KEYNOTE 158)
Condition: Multiple
Intervention: Not Applicable; Pembrolizumab (Keytruda)
Open

CLINICAL TRIAL 18941
Preoperative Extended Chemotherapy vs. Chemotherapy Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas
Condition: Gastrointestinal Tumor
Intervention: FOLFIRINOX; FOLFOX
Open

CLINICAL TRIAL 17985
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCB024360 in Combination With MEDI4736 in Subjects With Selected Advanced Solid Tumors
Condition: Multiple
Intervention: INCB024360 (Epacadostat); MEDI4736 (Durvalumab)
Open

CLINICAL TRIAL 18844
A Phase 2 Study of Cediranib in Combination with Olaparib in Advanced Solid Tumors
Condition: Multiple
Intervention: AZD2171 (Cediranib); Cediranib (Recentin); Olaparib (Lynparza)
Open

CLINICAL TRIAL 18891
A Multinational Open-Label, Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Administrations of NKR-2 in Patients with Different Metastatic Tumor Types
Condition: Malignant Hematology
Intervention: NKR-2
Open

CLINICAL TRIAL 18521
A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE)Compound KPT-8602 in Patients with Relapsed/Refractory Cancer Indications
Condition: Gastrointestinal Tumor
Intervention: Abiraterone acetate; Dexamethasone; KPT-8602; Zytiga (Abiraterone acetate)
Open

CLINICAL TRIAL 19112
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Condition: Multiple
Intervention: BMS-936558 (Nivolumab); Ipilimumab; Nivolumab; Yervoy (Ipilimumab)
Open

CLINICAL TRIAL 19114
Phase 1/2 Study to Evaluate the Safety and Preliminary Efficacy of Nivolumab Combined with Daratumumab in Participants with Advanced or Metastatic Solid Tumors
Condition: Multiple
Intervention: BMS-936558 (Nivolumab); Daratumumab; Nivolumab
Open

CLINICAL TRIAL 18141
Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
Condition: Gastrointestinal Tumor
Intervention: 748645 (Ibrutinib); Ibrutinib (Imbruvica); PCI-32765 (Ibrutinib)
Open

If you believe you are eligible for one of these trials or studies, please call
1-888-MOFFITT (1-888-663-3488).

Publications

  • Ashraf N, Kim R. Treatment of Gastric and Gastroesophageal Cancers-Do We Really Need Anthracyclines?. JAMA Oncol. 2017 Sep;3(9):1172-1173. Pubmedid: 27584978.
  • Sandoval-Sus JD, Mogollon-Duffo F, Patel A, Visweshwar N, Laber DA, Kim R, Jaglal MV. Nivolumab as salvage treatment in a patient with HIV-related relapsed/refractory Hodgkin lymphoma and liver failure with encephalopathy. J Immunother Cancer. 2017 Jun;5:49. Pubmedid: 28642818. Pmcid: PMC5477132.
  • Kim R, Chiorean EG, Amin M, Rocha-Lima CMS, Gandhi J, Harris WP, Song T, Portnoy D. Phase 2 study of combination SPI-1620 with docetaxel as second-line advanced biliary tract cancer treatment. Brit J Cancer. 2017 Jul;117(2):189-194. Pubmedid: 28632730. Pmcid: PMC5520510.
  • Chang YD, Smith J, Portman D, Kim R, Oberoi-Jassal R, Rajasekhara S, Davis M. Single Institute Experience With Methylphenidate and American Ginseng in Cancer-Related Fatigue. Am J Hosp Palliat Care. 2017 Jan. Pubmedid: 28299946.
  • Kim DW, Byer J, Kothari N, Mahipal A, Chang YD, Kim RD. EGFR Inhibitors in Patients with Advanced Squamous Cell Anal Carcinomas: A Single-Institution Experience. Oncology-Basel. 2017 Apr;92(4):190-196. Pubmedid: 28152526.
  • Kim DW, Talati C, Kim R. Hepatocellular carcinoma (HCC): beyond sorafenib-chemotherapy. J Gastrointest Oncol. 2017 Apr;8(2):256-265. Pubmedid: 28480065. Pmcid: PMC5401857.
  • Kothari N, Teer JK, Abbott AM, Srikumar T, Zhang Y, Yoder SJ, Brohl AS, Kim RD, Reed DR, Shibata D. Increased incidence of FBXW7 and POLE proofreading domain mutations in young adult colorectal cancers. Cancer. 2016 Sep;122(18):2828-2835. Pubmedid: 27244218. Pmcid: PMC5014625.
  • Mohammadi H, Abuodeh YA, Jin W, Frakes JM, Friedman M, Biebel B, Choi J, El-Haddad GE, Kis B, Sweeney J, Kim R, Pimiento JM, Malafa MP, Anaya D, Hoffe SE. Using the ALBI Grade as a Prognostic Marker for Radioembolization of Hepatocellular Carcinoma. Int J Radiat Oncol Biol Phys. 2016 Oct;96(2S):E194-E195.
  • Jin W, Mellon EA, Hoffe SE, Frakes JM, Springett GM, Centeno BA, Kim R, Mahipal A, Pimiento JM, Malafa MP, Latifi K. Does Metabolic Tumor Volume Predict Tumor Regression Grade After Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer?. Int J Radiat Oncol Biol Phys. 2016 Oct;96(2S):E195. Pubmedid: 27674030.
  • Pearson AL, Jin W, Mellon EA, Frakes JM, Strom T, Springett GM, Kim R, Mahipal A, Hodul PJ, Pimiento JM, Shridhar R, Malafa MP, Hoffe SE. Post-Stereotactic Body Radiation Therapy (SBRT) Neutrophil-to-Lymphocyte Ratio (NLR) in Patients With Borderline Resectable Pancreatic Cancer (BRPC) May Be a Prognostic Biomarker. Int J Radiat Oncol Biol Phys. 2016 Oct;96(2S):E153. Pubmedid: 27673917.
  • Pimiento JM, Davis-Yadley AH, Kim RD, Chen DT, Eikman EA, Berman CG, Malafa MP. Metabolic Activity by 18F-FDG-PET/CT Is Prognostic for Stage I and II Pancreatic Cancer. Clin Nucl Med. 2016 Mar;41(3):177-181. Pubmedid: 26673243. Pmcid: PMC4740191.
  • Bustamante L, Frakes J, Hoffe S, Kim R. Investigational drugs for treating anal cancer and future perspectives. Expert Opin Inv Drug. 2016 Jan;25(1):51-62. Pubmedid: 26560877.
  • Sajjad M, Batra S, Hoffe S, Kim R, Springett G, Mahipal A. Use of Radiation Therapy in Locally Advanced Pancreatic Cancer Improves Survival: A SEER Database Analysis. Am J Clin Oncol. 2016 Jan. Pubmedid: 26796313.
  • Kim R, Prithviraj GK, Shridhar R, Hoffe SE, Jiang K, Zhao X, Chen DT, Almhanna K, Strosberg J, Campos T, Shibata D. Phase I study of pre-operative continuous 5-FU and sorafenib with external radiation therapy in locally advanced rectal adenocarcinoma. Radiother Oncol. 2016 Feb;118(2):382-386. Pubmedid: 26861740.
  • Abuodeh Y, Naghavi AO, Ahmed KA, Venkat PS, Kim Y, Kis B, Choi J, Biebel B, Sweeney J, Anaya DA, Kim R, Malafa M, Frakes JM, Hoffe SE, El-Haddad G. Prognostic value of pre-treatment F-18-FDG PET-CT in patients with hepatocellular carcinoma undergoing radioembolization. World J Gastroenterol. 2016 Dec;22(47):10406-10414. Pubmedid: 28058021. Pmcid: PMC5175253.
  • Abdul Razak AR, Mau-Soerensen M, Gabrail NY, Gerecitano JF, Shields AF, Unger TJ, Saint-Martin JR, Carlson R, Landesman Y, McCauley D, Rashal T, Lassen U, Kim R, Stayner LA, Mirza MR, Kauffman M, Shacham S, Mahipal A. First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors. J Clin Oncol. 2016 Dec;34(34):4142-4150. Pubmedid: 26926685. Pmcid: PMC5562433.
  • Doepker MP, Thompson ZJ, Centeno BA, Kim RD, Wong J, Hodul PJ. Clinicopathologic and survival analysis of resected ampullary adenocarcinoma. J Surg Oncol. 2016 Aug;114(2):170-175. Pubmedid: 27158031.
  • Kim R, Yamauchi T, Husain K, Sebti S, Malafa M. Triciribine Phosphate Monohydrate, an AKT Inhibitor, Enhances Gemcitabine Activity in Pancreatic Cancer Cells. Anticancer Res. 2015 Sep;35(9):4599-4604. Pubmedid: 26254348.
  • Abbott AM, Kim R, Hoffe SE, Arslan B, Biebel B, Choi J, El-Haddad G, Kis B, Sweeney J, Meredith KL, Almhanna K, Strosberg J, Shibata D, Fulp WJ, Shridhar R. Outcomes of Therasphere Radioembolization for Colorectal Metastases. Clin Colorectal Cancer. 2015 Sep;14(3):146-153. Pubmedid: 25795047.
  • Suleiman Y, Mahipal A, Shibata D, Siegel EM, Jump H, Fulp WJ, Springett GM, Kim R. Phase I study of combination of pasireotide LAR + gemcitabine in locally advanced or metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2015 Sep;76(3):481-487. Pubmedid: 26126727.
  • Mahipal A, Shibata D, Siegel E, Springett G, Almhanna K, Fulp W, Williams-Elson I, Kim R. Phase I trial of combination of FOLFIRI and pasireotide, a somatostatin analogue, in advanced gastrointestinal malignancies. Invest New Drugs. 2015 Oct;33(5):1093-1099. Pubmedid: 26275531.
  • Denson A, Burke N, Wapinsky G, Bertels B, Juan TH, Lee J, Springett GM, Strosberg JR, Kim RD, Sullivan DM, Mahipal A. Clinical Outcomes of Patients With Gastrointestinal Malignancies Participating in Phase I Clinical Trials. Am J Clin Oncol. 2015 Oct. Pubmedid: 26523441. Pmcid: PMC4980275.
  • Mahipal A, Choi M, Kim R. Second-Line Treatment of Advanced Gastric Cancer: Where Do We Stand?. J Natl Compr Canc Ne. 2015 Oct;13(10):1281-1291. Pubmedid: 26483065.
  • Kim R, Prithviraj G, Kothari N, Springett G, Malafa M, Hodul P, Kim J, Yue B, Morse B, Mahipal A. PET/CT Fusion Scan Prevents Futile Laparotomy in Early Stage Pancreatic Cancer. Clin Nucl Med. 2015 Nov;40(11):e501-e505. Pubmedid: 26053713. Pmcid: PMC4813735.
  • Kim R, Schell MJ, Teer JK, Greenawalt DM, Yang M, Yeatman TJ. Co-evolution of somatic variation in primary and metastatic colorectal cancer may expand biopsy indications in the molecular era. PLoS One. 2015 May;10(5):e0126670. Pubmedid: 25974029. Pmcid: PMC4431733.
  • Ashraf N, Hoffe S, Kim R. Locally advanced gastroesophageal junction tumor: a treatment dilemma. Oncologist. 2015 Feb;20(2):134-142. Pubmedid: 25561508. Pmcid: PMC4319638.
  • Kang YK, Yau T, Park JW, Lim HY, Lee TY, Obi S, Chan SL, Qin S, Kim RD, Casey M, Chen C, Bhattacharyya H, Williams JA, Valota O, Chakrabarti D, Kudo M. Randomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma. Ann Oncol. 2015 Dec. Pubmedid: 26386123.
  • Kothari N, Kim R, Jorissen RN, Desai J, Tie J, Wong HL, Farragher I, Jones I, Day FL, Li S, Sakthinandeswaren A, Palmieri M, Lipton L, Schell M, Teer JK, Shibata D, Yeatman T, Sieber OM, Gibbs P, Tran B. Impact of regular aspirin use on overall and cancer-specific survival in patients with colorectal cancer harboring a PIK3CA mutation. Acta Oncol. 2015 Apr;54(4):487-492. Pubmedid: 25549537. Pmcid: PMC4743650.
  • Sanoff HK, Kim R, Ivanova A, Alistar A, McRee AJ, O'Neil BH. Everolimus and pasireotide for advanced and metastatic hepatocellular carcinoma. Invest New Drugs. 2015 Apr;33(2):505-509. Pubmedid: 25613083. Pmcid: PMC4487887.
  • Ashraf N, Hoffe S, Kim R. Adjuvant treatment for gastric cancer: chemotherapy versus radiation. Oncologist. 2014 Sep;18(9):1013-1021. Pubmedid: 23966224. Pmcid: PMC3780633.
  • Kim R, Byer J, Fulp WJ, Mahipal A, Dinwoodie W, Shibata D. Carboplatin and paclitaxel treatment is effective in advanced anal cancer. Oncology-Basel. 2014 Sep;87(2):125-132. Pubmedid: 25012155.
  • Kothari N, Schell MJ, Teer JK, Yeatman T, Shibata D, Kim R. Comparison of KRAS mutation analysis of colorectal cancer samples by standard testing and next-generation sequencing. J Clin Pathol. 2014 Sep;67(9):764-767. Pubmedid: 25004944. Pmcid: PMC4743643.
  • Ashraf N, Kothari N, Kim R. Predictive biomarkers for anti-epidermal growth factor receptor therapy: beyond KRAS testing. J Natl Compr Canc Ne. 2014 Oct;12(10):1433-1442. Pubmedid: 25313182.
  • Fujiki M, Aucejo F, Choi M, Kim R. Neo-adjuvant therapy for hepatocellular carcinoma before liver transplantation: where do we stand?. World J Gastroenterol. 2014 May;20(18):5308-5319. Pubmedid: 24833861. Pmcid: PMC4017046.
  • Waghray A, Balci B, El-Gazzaz G, Kim R, Pelley R, Menon KN, Estfan B, Romero-Marrero C, Aucejo F. Safety and efficacy of sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation. Clin Transplant. 2014 Mar;27(4):555-561. Pubmedid: 23758296.
  • Ashraf N, Hoffe S, Kim R. French FNCLCC/FFCD 9703 study. Oncologist. 2014 Apr;19(4):431. Pubmedid: 24729607. Pmcid: PMC3983828.
  • Kim R, Tan A, Choi M, El-Rayes BF. Geographic differences in approach to advanced gastric cancer: Is there a standard approach?. Crit Rev Oncol Hematol. 2013 Nov;88(2):416-426. Pubmedid: 23764501.
  • Kothari N, Saif MW, Kim R. First-line treatment for advanced pancreatic cancer. JOP. 2013 Mar;14(2):129-132. Pubmedid: 23474553.
  • Kim R, Mahipal A, Choi M, Saif MW. Biomarkers for pancreatic cancer: is it ready for primetime?. JOP. 2013 Jul;14(4):309-311. Pubmedid: 23846914.
  • Xie H, Jiang W, Jiang J, Wang Y, Kim R, Liu X, Liu X. Predictive and prognostic roles of ribonucleotide reductase M1 in resectable pancreatic adenocarcinoma. Cancer. 2013 Jan;119(1):173-181. Pubmedid: 22736490.
  • Estfan B, Byrne M, Kim R. Sorafenib in advanced hepatocellular carcinoma: hypertension as a potential surrogate marker for efficacy. Am J Clin Oncol. 2013 Aug;36(4):319-324. Pubmedid: 22547010.
  • Strosberg JR, Yeatman T, Weber J, Coppola D, Schell MJ, Han G, Almhanna K, Kim R, Valone T, Jump H, Sullivan D. A phase II study of RO4929097 in metastatic colorectal cancer. Eur J Cancer. 2012 May;48(7):997-1003. Pubmedid: 22445247. Pmcid: PMC4522922.
  • Kim R, Byer J, Saif MW. BRCA and Pancreatic Cancer: Selection of Chemotherapy. JOP. 2012 Mar;13(2):180-181. Pubmedid: 22406596.
  • Choi M, Kim R, Saif MW. What options are available for refractory pancreatic cancer?. JOP. 2012 Mar;13(2):163-165. Pubmedid: 22406591.
  • Kim R, Kubal T. To give or not to give anti-epidermal growth factor receptor (EGFR) monoclonal antibodies to patients with KRAS G13D mutation in advanced colorectal cancer. Clin Colorectal Cancer. 2012 Jun;11(2):85-87. Pubmedid: 22169039.
  • Choi M, Razzaque S, Kim R. Systemic therapy of advanced pancreatic cancer: has the landscape changed?. Clin Adv Hematol Oncol. 2012 Jul;10(7):442-451. Pubmedid: 22895284.
  • Lazaryan A, Kalmadi S, Almhanna K, Pelley R, Kim R. Predictors of clinical outcomes of resected ampullary adenocarcinoma: a single-institution experience. Eur J Surg Oncol. 2011 Sep;37(9):791-797. Pubmedid: 21741199.
  • Fujiki M, Aucejo F, Kim R. General overview of neo-adjuvant therapy for hepatocellular carcinoma before liver transplantation: necessity or option?. Liver Int. 2011 Sep;31(8):1081-1089. Pubmedid: 22008644.
  • Kim R, Aucejo F. Radiologic complete response with sirolimus and sorafenib in a hepatocellular carcinoma patient who relapsed after orthotopic liver transplantation. J Gastrointest Cancer. 2011 Mar;42(1):50-53. Pubmedid: 20714941.
  • Kim R, Byrne MT, Tan A, Aucejo F. What is the indication for sorafenib in hepatocellular carcinoma? A clinical challenge. Oncology (Williston Park). 2011 Mar;25(3):283-91, 295. Pubmedid: 21548473.
  • Liu X, Jiang W, Aucejo F, Kim R, Miller C, Byrne M, Lopez R, Yerian L. Insulin-like growth factor I receptor β expression in hepatocellular carcinoma. Hum Pathol. 2011 Jun;42(6):882-891. Pubmedid: 21292299.
  • Kim R, Chabot J, Saif MW. Adjuvant Treatment for Ampullary Cancer. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011. JOP. 2011 Jul;12(4):362-363. Pubmedid: 21737897.
  • Kim R, Tan A, Lai KK, Jiang J, Wang Y, Rybicki LA, Liu X. Prognostic roles of human equilibrative transporter 1 (hENT-1) and ribonucleoside reductase subunit M1 (RRM1) in resected pancreatic cancer. Cancer. 2011 Jul;117(14):3126-3134. Pubmedid: 21264835.
  • Kim R. FOLFIRINOX: a new standard treatment for advanced pancreatic cancer?. Lancet Oncol. 2011 Jan;12(1):8-9. Pubmedid: 21050812.
  • Lance C, McLennan G, Obuchowski N, Cheah G, Levitin A, Sands M, Spain J, Srinivas S, Shrikanthan S, Aucejo FN, Kim R, Menon KV. Comparative analysis of the safety and efficacy of transcatheter arterial chemoembolization and yttrium-90 radioembolization in patients with unresectable hepatocellular carcinoma. J Vasc Interv Radiol. 2011 Dec;22(12):1697-1705. Pubmedid: 21983055.
  • Kim R, Menon N, Aucejo F. Safe use of sorafenib in a patient undergoing salvage liver transplantation for recurrent hepatocellular carcinoma after hepatic resection. Med Oncol. 2011 Dec;28(4):1044-1047. Pubmedid: 20635167.
  • Kim R, El-Gazzaz G, Tan A, Elson P, Byrne M, Chang YD, Aucejo F. Safety and feasibility of using sorafenib in recurrent hepatocellular carcinoma after orthotopic liver transplantation. Oncology-Basel. 2010 Nov;79(1-2):62-66. Pubmedid: 21071991.
  • Phillips B, Kalady M, Kim R. BRAF testing in advanced colorectal cancer: is it ready for prime time?. Clin Adv Hematol Oncol. 2010 Jun;8(6):437-444. Pubmedid: 20733556.
  • Tan A, Aucejo F, Kim R. Is there a role for adjuvant treatment after hepatic resection for hepatocellular carcinoma?. Oncology. 2010 Jun;78(3-4):161-171. Pubmedid: 20530972.
  • Kim R, Tsao R, Tan A, Byrne M, Almhanna K, Lazaryan A, Elson P, Pelley RJ. A single institution review of adjuvant therapy outcomes for resectable pancreatic adenocarcinoma: outcome and prognostic indicators. J Gastrointest Surg. 2010 Jul;14(7):1159-1169. Pubmedid: 20446118.
  • Wesolowski R, Lee C, Kim R. Is there a role for second-line chemotherapy in advanced gastric cancer?. Lancet Oncol. 2009 Sep;10(9):903-912. Pubmedid: 19717092.
  • Anderson C, Kim R. Adjuvant therapy for resected extrahepatic cholangiocarcinoma: a review of the literature and future directions. Cancer Treat Rev. 2009 Jun;35(4):322-327. Pubmedid: 19147294.
  • Aucejo F, Kim R, Zein N, Quintini C, Uso TD, Lopez R, Eghtesad B, Fung J, Miller C, Yerian L. Vascular endothelial growth factor receptor 2 expression in non-tumorous cirrhotic liver is higher when hepatoma is beyond Milan criteria. Liver Transpl. 2009 Feb;15(2):169-176. Pubmedid: 19177438.
  • Kim R. Cetuximab and panitumumab: are they interchangeable?. Lancet Oncol. 2009 Dec;10(12):1140-1141. Pubmedid: 19875336.
  • Kim R, Tan A, Estfan B, Aucejo F. Adjuvant treatment after orthotopic liver transplantation: is it really necessary?. Oncology (Williston Park). 2009 Dec;23(14):1276-1281. Pubmedid: 20120841.
  • Almhanna K, Kim R. Second-line therapy for gemcitabine-refractory pancreatic cancer: is there a standard?. Oncology (Williston Park). 2008 Sep;22(10):1176-1183. Pubmedid: 18935928.
  • Saif MW, Hashmi S, Zelterman D, Almhanna K, Kim R. Capecitabine vs continuous infusion 5-FU in neoadjuvant treatment of rectal cancer. A retrospective review. Int J Colorectal Dis. 2008 Feb;23(2):139-145. Pubmedid: 17909820.
  • Saif MW, Kim R. Role of platinum agents in the management of advanced pancreatic cancer. Expert Opin Pharmacother. 2007 Nov;8(16):2719-2727. Pubmedid: 17956194.
  • Kim R, Saif MW. Is there an optimal neoadjuvant therapy for locally advanced pancreatic cancer?. JOP. 2007 May;8(3):279-288. Pubmedid: 17495356.
  • Saif MW, Kim R. Incidence and management of cutaneous toxicities associated with cetuximab. Expert Opin Drug Saf. 2007 Mar;6(2):175-182. Pubmedid: 17367263.
  • Almhanna K, Kalmadi S, Pelley R, Kim R. Neoadjuvant therapy for hepatocellular carcinoma: is there an optimal approach?. Oncology (Williston Park). 2007 Aug;21(9):1116-1122. Pubmedid: 17910314.